π Novo Nordisk needs a plan post-weight loss boom
Novo Nordisk, the maker of Wegovy, is facing increasing pressure from investors. Stakeholders are demanding the company develop a clear strategy beyond just weight-loss pharmaceuticals. This focus comes as the market heavily values their recent success in obesity treatment. The company needs to demonstrate growth avenues for the future beyond these blockbuster drugs. Novo Nordisk must now pivot to secure long-term relevance in the pharma sector. π